CardioVascular BioTheraputics, Inc. (CVBT) is a biopharmaceutical company focused on introducing new therapies for cardiovascular disease.

FGF-1141, the active ingredient in our drug candidates, is a protein, and is a member of the fibroblast growth factor family. Fibroblast Growth Factor-1 or, FGF-1, is a powerful stimulator of new blood vessel growth, a process referred to in the scientific community as “angiogenesis.” This is due to the fact that FGF-stimulates the growth and multiplication of the two main cell types of blood vessels, smooth muscle cells and endothelial cells. Extensive work by CVBT and others has shown that, when FGF-1 is injected into the tissue and organs of animals with experimentally atherosclerotic disease, new blood vessels grow in the injected areas. Proteins such as FGF-1141 represent a novel therapy for diseases characterized by inadequate blood flow to a tissue or organ. This growth factor is being tested in a wide variety of human diseases that could benefit from increased angiogenesis, including coronary artery disease, stroke, peripheral artery disease of the legs and wound healing.

FDA-authorized clinical trials are being performed in the USA in patients with coronary artery disease with promising results. Additional trials are planned for the near future with our drug candidates for diabetics with wound healing deficiencies and vascular disease in their legs. Animal studies that mimic these human conditions have been performed and indicated that FGF-1141 is an effective treatment in both animal models of wound healing and peripheral vascular disease. The large numbers of patients that suffer from these cardiovascular diseases make each of these medical indications a potential significant market.

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.